Comparative Pharmacology
Head-to-head clinical analysis: EDARBYCLOR versus HYDROPRES 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDARBYCLOR versus HYDROPRES 25.
EDARBYCLOR vs HYDROPRES 25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
EDARBYCLOR is a fixed-dose combination of azilsartan medoxomil, an angiotensin II receptor blocker (ARB), and chlorthalidone, a thiazide-like diuretic. Azilsartan selectively blocks AT1 receptors, reducing angiotensin II-mediated vasoconstriction, aldosterone secretion, and renal sodium reabsorption. Chlorthalidone inhibits sodium-chloride cotransport in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Reserpine depletes catecholamines from central and peripheral nerve terminals by inhibiting vesicular monoamine uptake, leading to decreased sympathetic outflow.
One tablet (azilsartan medoxomil 40 mg / chlorthalidone 12.5 mg or 40 mg / 25 mg) orally once daily.
1 tablet orally once daily, each tablet contains hydrochlorothiazide 25 mg and reserpine 0.125 mg. Dosage may be increased to 2 tablets daily if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 11-12 hours for azilsartan medoxomil; clinical consequence: supports once-daily dosing for 24-hour blood pressure control
Hydrochlorothiazide: 6-15 hr; reserpine: 50-100 hr (terminal, with prolonged adrenergic depletion lasting days)
Renal (approximately 60% as unchanged drug and metabolites), biliary/fecal (approximately 40%)
Renal: hydrochlorothiazide 70% unchanged, reserpine ~30% unchanged; fecal: reserpine ~60% metabolites
Category C
Category C
Angiotensin II Receptor Blocker/Thiazide Diuretic Combination
Thiazide Diuretic Combination